Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis
A Lemarquis, T Campbell, M Aranda-Guillén… - Journal of Allergy and …, 2021 - jacionline.org
Autoimmune polyendocrine syndrome type 1 (APS1) is characterized by neutralizing aAbs
to type I IFNs. 5 As a proof-of-concept, we present the case of a child with APS1 and aAbs to
type I IFN who developed life-threatening COVID-19 and responded rapidly to treatment with
plasmapheresis, intravenous immunoglobulin (IVIg), and high-dosage corticosteroids. The
patient is an 8-year-old girl with APS1, verified by homozygous AIRE [c. 1616C> T (p.
Pro539Leu)] mutations, typical clinical presentation including Addison disease …
to type I IFNs. 5 As a proof-of-concept, we present the case of a child with APS1 and aAbs to
type I IFN who developed life-threatening COVID-19 and responded rapidly to treatment with
plasmapheresis, intravenous immunoglobulin (IVIg), and high-dosage corticosteroids. The
patient is an 8-year-old girl with APS1, verified by homozygous AIRE [c. 1616C> T (p.
Pro539Leu)] mutations, typical clinical presentation including Addison disease …